Sweden's Xbrane Q4 revenue falls sharply

Xbrane Biopharma AB

20/02/2026 07:16

Overview

Sweden-based biosimilar developer's Q4 revenue fell sharply

Company reported Q4 net loss shrunk to SEK 26.5 mln

Company completed reverse share split and signed financing agreement with Fenja Capital

Outlook

Company expects to resubmit BLA to FDA in March 2026

Xbrane did not provide specific financial guidance for 2026

Result Drivers

REVENUE DECLINE - Q4 revenue decreased significantly due to a drop in nonrecurring license revenue

FDA RESPONSE - FDA issued a Complete Response Letter for ranibizumab biosimilar candidate, affecting potential revenue

R&D INVESTMENT - High R&D costs accounted for 65% of total operating costs, reflecting focus on development

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
SEK 9.10 mln
Q4 EPS
-SEK 0.06
Q4 Net Income
-SEK 26.50 mln
Q4 EBITDA
-SEK 21.90 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Xbrane Biopharma AB is SEK62.50, about 524.9% above its February 19 closing price of SEK10.00

Press Release: ID:nMFN7cwQw9

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)